Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 10/2018

01.10.2018 | Myocardial Disease (A Abbate, Section Editor)

Genetics of Dilated Cardiomyopathy: Clinical Implications

verfasst von: A. Paldino, G. De Angelis, M. Merlo, M. Gigli, M. Dal Ferro, G. M. Severini, L. Mestroni, G. Sinagra

Erschienen in: Current Cardiology Reports | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review aims to summarize the current knowledge on the genetic background of dilated cardiomyopathy (DCM), with particular attention to the genotype-phenotype correlations and the possible implications for clinical management.

Recent Findings

Next generation sequencing (NGS) has led to the identification of an increasing number of genes and mutations responsible for DCM. This genetic variability is probably related to the extreme heterogeneity of disease manifestation. Important findings have associated mutations of Lamin A/C (LMNA) and Filamin C (FLNC) to poor prognosis and the propensity to cause an arrhythmic phenotype, respectively. However, a deeper understanding of the genotype-phenotype correlation is necessary, because it could have several implications for the clinical management of the patients. Furthermore, the correct interpretation of pathogenicity of mutations and the clinical impact of genetic testing in DCM patients still represent important fields to be implemented.

Summary

A pathogenic gene mutation can be identified in almost 40% of DCM patients. The recent discoveries and future research in the field of genotype-phenotype correlation may lead to a more personalized management of the mutation carriers towards the application of precision medicine in DCM.
Literatur
1.
2.
Parikh VN, Ashley EA. Next-generation sequencing in cardiovascular disease: present clinical applications and the horizon of precision medicine. Circulation. 2017;135:406–9.CrossRefPubMedPubMedCentral
3.
Favalli V, Serio A, Grasso M, Arbustini E. Genetic causes of dilated cardiomyopathy. Heart. 2016;102:2004–14.CrossRefPubMed
4.
•• Haas J, Frese KS, Peil B, et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J. 2015;36:1123–35. This article is the most comprehensive study on the distribution of genes, the number of mutations and mutational burden of patients with DCM. CrossRefPubMed
5.
Sturm AC, Hershberger RE. Genetic testing in cardiovascular medicine: current landscape and future horizons. Curr Opin Cardiol. 2013;28:317–25.PubMed
6.
7.
Walsh R, Thomson KL, Ware JS, Funke BH, Woodley J, McGuire KJ, et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med. 2017;19:192–203.CrossRefPubMed
8.
Nouhravesh N, Ahlberg G, Ghouse J, Andreasen C, Svendsen JH, Haunsø S, et al. Analyses of more than 60,000 exomes questions the role of numerous genes previously associated with dilated cardiomyopathy. Mol Genet Genomic Med. 2016;4:617–23.CrossRefPubMedPubMedCentral
9.
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.CrossRefPubMedPubMedCentral
10.
11.
12.
13.
Hershberger RE, Norton N, Morales A, Li D, Siegfried JD, Gonzalez-Quintana J. Coding sequence rare variants identified in MYBPC3, MYH6, TPM1, TNNC1, and TNNI3 from 312 patients with familial or idiopathic dilated cardiomyopathy. Circ Cardiovasc Genet. 2010;3:155–61.CrossRefPubMedPubMedCentral
14.
Kushner JD, Nauman D, Burgess D, Ludwigsen S, Parks SB, Pantely G, et al. Clinical characteristics of 304 kindreds evaluated for familial dilated cardiomyopathy. J Card Fail. 2006;12:422–9.CrossRefPubMed
15.
Siegfried JD, Morales A, Kushner JD, Burkett E, Cowan J, Mauro AC, et al. Return of genetic results in the familial dilated cardiomyopathy research project. J Genet Couns. 2013;22:164–74.CrossRefPubMed
16.
Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10:531–47.CrossRefPubMed
17.
Herman DS, Lam L, Taylor MRG, Wang L, Teekakirikul P, Christodoulou D, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012;366:619–28.CrossRefPubMedPubMedCentral
18.
19.
20.
Pugh TJ, Kelly MA, Gowrisankar S, Hynes E, Seidman MA, Baxter SM, et al. The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. Genet Med. 2014;16:601–8.CrossRefPubMed
21.
• Dal Ferro M, Stolfo D, Altinier A, et al. Association between mutation status and left ventricular reverse remodelling in dilated cardiomyopathy. Heart. 2017;103:1704–10. This study provides the important evidence that the response to therapy in terms of LVRR could be influenced by the mutational status (especially, cytoskeleton Z-disk rare variants are associater with lower rate of reverse remodeling). CrossRefPubMed
22.
Begay RL, Graw SL, Sinagra G, Asimaki A, Rowland TJ, Slavov DB, et al. Filamin C truncation mutations are associated with arrhythmogenic dilated cardiomyopathy and changes in the cell–cell adhesion structures. JACC Clin Electrophysiol. 2018;4:504–14.CrossRefPubMedPubMedCentral
23.
• Ortiz-Genga MF, Cuenca S, Dal Ferro M, et al. Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. J Am Coll Cardiol. 2016;68:2440–51. This article is important because it provides the evidence of an arrhythmogenic phenotype caused by FLNC mutations in a relatively large cohort of patients. CrossRefPubMed
24.
Taylor MRG, Slavov D, Ku L, di Lenarda A, Sinagra G, Carniel E, et al. Prevalence of desmin mutations in dilated cardiomyopathy. Circulation. 2007;115:1244–51.CrossRefPubMed
25.
Politano L, Nigro V, Nigro G, Petretta VR, Passamano L, Papparella S, et al. Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies. J Am Med Assoc. 1996;275:1335–8.CrossRef
26.
Taylor MRG, Fain PR, Sinagra G, Robinson ML, Robertson AD, Carniel E, et al. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol. 2003;41:771–80.CrossRefPubMed
27.
Elliott P, O’Mahony C, Syrris P, Evans A, Sorensen CR, Sheppard MN, et al. Prevalence of desmosomal protein gene mutations in patients with dilated cardiomyopathy. Circ Cardiovasc Genet. 2010;3:314–22.CrossRefPubMed
28.
Menon SC, Michels VV, Pellikka PA, Ballew JD, Karst ML, Herron KJ, et al. Cardiac troponin T mutation in familial cardiomyopathy with variable remodeling and restrictive physiology. Clin Genet. 2008;74:445–54.CrossRefPubMedPubMedCentral
29.
Roncarati R, Viviani Anselmi C, Krawitz P, Lattanzi G, von Kodolitsch Y, Perrot A, et al. Doubly heterozygous LMNA and TTN mutations revealed by exome sequencing in a severe form of dilated cardiomyopathy. Eur J Hum Genet. 2013;21:1105–11.CrossRefPubMedPubMedCentral
30.
Wessels MW, Herkert JC, Frohn-Mulder IM, Dalinghaus M, Van Den Wijngaard A, De Krijger RR, et al. Compound heterozygous or homozygous truncating MYBPC3 mutations cause lethal cardiomyopathy with features of noncompaction and septal defects. Eur J Hum Genet. 2015;23:922–8.CrossRefPubMed
31.
Frantz S, Falcao-Pires I, Balligand JL, Bauersachs J, Brutsaert D, Ciccarelli M, et al. The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. Eur J Heart Fail. 2018;20:445–59.CrossRefPubMed
32.
Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med. 2016;374:233–41.
33.
Deshmukh PM, Krishnamani R, Romanyshyn M, Johnson AK, Noti JD. Association of angiotensin converting enzyme gene polymorphism with tachycardia cardiomyopathy. Int J Mol Med. 2004;13:455–8.PubMed
34.
Guzzo-merello G, Cobo-marcos M, Gallego-delgado M, Garcia-pavia P, Guzzo-merello G, Cobo-marcos M, et al. Alcoholic cardiomyopathy. World J Cardiol. 2014;6:771–81.CrossRefPubMedPubMedCentral
35.
36.
37.
Zorzi A, Pelliccia A, Corrado D. Inherited cardiomyopathies and sports participation. Netherlands Hear J. 2018;26:154–65.CrossRef
38.
Kirchhof P, Fabritz L, Zwiener M, Witt H, Schafers M, Zellerhoff S, et al. Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation. 2006;114:1799–806.CrossRefPubMed
39.
Hazebroek MR, Moors S, Dennert R, van den Wijngaard A, Krapels I, Hoos M, et al. Prognostic relevance of gene-environment interactions in patients with dilated cardiomyopathy applying the MOGE(S) classification. J Am Coll Cardiol. 2015;66:1313–23.CrossRefPubMed
40.
Charron P, Arad M, Arbustini E, Basso C, Bilinska Z, Elliott P, et al. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2010;31:2715–28.CrossRefPubMed
41.
• Merlo M, Cannatà A, Gobbo M, Stolfo D, Elliott PM, Sinagra G. Evolving concepts in dilated cardiomyopathy. Eur J Heart Fail. 2018;20(2):228–39. This review offers a comprehensive survey of emerging issues in the clinical management of DCM, providing where possible practical recommendations. CrossRefPubMed
42.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016:37:2129–2200m.
43.
Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Europace. 2011;13:1077–109.CrossRefPubMed
44.
Hershberger RE, Lindenfeld J, Mestroni L, Seidman CE, Taylor MRG, Towbin JA, Heart Failure Society of America. Genetic evaluation of cardiomyopathy—a Heart Failure Society of America practice guideline. J Card Fail 2009:15:83–97.CrossRefPubMed
45.
Moretti M, Merlo M, Barbati G, Di Lenarda A, Brun F, Pinamonti B, et al. Prognostic impact of familial screening in dilated cardiomyopathy. Eur J Heart Fail. 2010;12:922–7.CrossRefPubMed
46.
van Spaendonck-Zwarts KY, van den Berg MP, van Tintelen JP. DNA analysis in inherited cardiomyopathies: current status and clinical relevance. Pacing Clin Electrophysiol. 2008;31:S46–9.CrossRefPubMed
47.
Fatkin D, Yeoh T, Hayward CS, Benson V, Sheu A, Richmond Z, et al. Evaluation of left ventricular enlargement as a marker of early disease in familial dilated cardiomyopathy. Circ Cardiovasc Genet. 2011;4:342–8.CrossRefPubMed
48.
• Hasselberg NE, Haland TF, Saberniak J, Brekke PH, Berge KE, Leren TP, et al. Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation. Eur Heart J. 2018;39:853–60. This article provides the prevalence and cardiac penetrance of lamin mutation in a large norwegian DCM cohort. CrossRefPubMed
49.
Lakdawala NK, Thune JJ, Colan SD, Cirino AL, Farrohi F, Rivero J, et al. Subtle abnormalities in contractile function are an early manifestation of sarcomere mutations in dilated cardiomyopathy. Circ Cardiovasc Genet. 2012;5:503–10.CrossRefPubMedPubMedCentral
50.
51.
Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;2015(36):2793–867.CrossRef
52.
Gerull B, Gramlich M, Atherton J, McNabb M, Trombitás K, Sasse-Klaassen S, et al. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat Genet. 2002;30:201–4.CrossRefPubMed
53.
• Verdonschot JAJ, Hazebroek MR, Derks KWJ, et al. Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias. Eur Heart J. 2018;39:864–73. This article shows the structural and metabolic alterations that carachterize heart with titin truncating mutations. CrossRefPubMed
54.
Tayal U, Newsome S, Buchan R, Whiffin N, Halliday B, Lota A, et al. Phenotype and clinical outcomes of titin cardiomyopathy. J Am Coll Cardiol. 2017;70:2264–74.CrossRefPubMedPubMedCentral
55.
56.
Garcia-Pavia P, Syrris P, Salas C, Evans A, Mirelis JG, Cobo-Marcos M, et al. Desmosomal protein gene mutations in patients with idiopathic dilated cardiomyopathy undergoing cardiac transplantation: a clinicopathological study. Heart. 2011;97:1744–52.CrossRefPubMed
57.
Capetanaki Y, Papathanasiou S, Diokmetzidou A, Vatsellas G, Tsikitis M. Desmin related disease: a matter of cell survival failure. Curr Opin Cell Biol. 2015;32:113–20.CrossRefPubMed
58.
Arbustini E, Pasotti M, Pilotto A, Pellegrini C, Grasso M, Previtali S, et al. Desmin accumulation restrictive cardiomyopathy and atrioventricular block associated with desmin gene defects. Eur J Heart Fail. 2006;8:477–83.CrossRefPubMed
59.
Schmitt JP, Kamisago M, Asahi M, Li GH, Ahmad F, Mende U, et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science. 2003;299:1410–3.CrossRefPubMed
60.
Fish M, Shaboodien G, Kraus S, Sliwa K, Seidman CE, Burke MA, et al. Mutation analysis of the phospholamban gene in 315 South Africans with dilated, hypertrophic, peripartum and arrhythmogenic right ventricular cardiomyopathies. Sci Rep. 2016;6:22235.CrossRefPubMedPubMedCentral
61.
Haghighi K, Kolokathis F, Gramolini AO, Waggoner JR, Pater L, Lynch RA, et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc Natl Acad Sci. 2006;103:1388–93.CrossRefPubMedPubMedCentral
62.
van der Zwaag PA, van Rijsingen IAW, Asimaki A, Jongbloed JDH, van Veldhuisen DJ, Wiesfeld ACP, et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail. 2012;14:1199–207.CrossRefPubMedPubMedCentral
63.
McNair WP, Sinagra G, Taylor MRG, di Lenarda A, Ferguson DA, Salcedo EE, et al. SCN5A mutations associate with arrhythmic dilated cardiomyopathy and commonly localize to the voltage-sensing mechanism. J Am Coll Cardiol. 2011;57:2160–8.CrossRefPubMed
64.
65.
66.
Benedetti S, Menditto I, Degano M, Rodolico C, Merlini L, D'Amico A, et al. Phenotypic clustering of lamin A/C mutations in neuromuscular patients. Neurology. 2007;69:1285–92.CrossRefPubMed
67.
Chen L, Lee L, Kudlow BA, Dos Santos HG, Sletvold O, Shafeghati Y, et al. LMNA mutations in atypical Werner’s syndrome. Lancet. 2003;362:440–5.CrossRefPubMed
68.
Van Rijsingen IAW, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: a European cohort study. J Am Coll Cardiol. 2012;59:493–500.CrossRefPubMed
69.
van Rijsingen IAW, Nannenberg EA, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, et al. Gender-specific differences in major cardiac events and mortality in lamin A/C mutation carriers. Eur J Heart Fail. 2013;15:376–84.CrossRefPubMed
70.
Pasotti M, Klersy C, Pilotto A, Marziliano N, Rapezzi C, Serio A, et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol. 2008;52:1250–60.CrossRefPubMed
71.
72.
Vorgerd M, van der Ven PFM, Bruchertseifer V, Löwe T, Kley RA, Schröder R, et al. A mutation in the dimerization domain of filamin C causes a novel type of autosomal dominant myofibrillar myopathy. Am J Hum Genet. 2005;77:297–304.CrossRefPubMedPubMedCentral
73.
Kley RA, Hellenbroich Y, van der Ven PFM, Furst DO, Huebner A, Bruchertseifer V, et al. Clinical and morphological phenotype of the filamin myopathy: a study of 31 German patients. Brain. 2007;130:3250–64.CrossRefPubMed
74.
75.
76.
Stossel TP, Condeelis J, Cooley L, Hartwig JH, Noegel A, Schleicher M, et al. Filamins as integrators of cell mechanics and signalling. Nat Rev Mol Cell Biol. 2001;2:138–45.CrossRefPubMed
77.
Zhou A-X, Hartwig JH, Akyürek LM. Filamins in cell signaling, transcription and organ development. Trends Cell Biol. 2010;20:113–23.CrossRefPubMed
78.
79.
80.
Hastings R, De Villiers CP, Hooper C, et al. Combination of whole genome sequencing, linkage, and functional studies implicates a missense mutation in titin as a cause of autosomal dominant cardiomyopathy with features of left ventricular noncompaction. Circ Cardiovasc Genet. 2016;9:426–35.CrossRefPubMedPubMedCentral
81.
Sarantitis I, Papanastasopoulos P, Manousi M, Baikoussis NG, Apostolakis E. The cytoskeleton of the cardiac muscle cell. Hell J Cardiol. 2012;53:367–79.
82.
83.
Liu G-S, Morales A, Vafiadaki E, Lam CK, Cai W-F, Haghighi K, et al. A novel human R25C-phospholamban mutation is associated with super-inhibition of calcium cycling and ventricular arrhythmia. Cardiovasc Res. 2015;107:164–74.CrossRefPubMedPubMedCentral
84.
te Rijdt WP, van Tintelen JP, Vink A, van der Wal AC, de Boer RA, van den Berg MP, et al. Phospholamban p.Arg14del cardiomyopathy is characterized by phospholamban aggregates, aggresomes, and autophagic degradation. Histopathology. 2016;69:542–50.CrossRef
85.
86.
87.
Liang P, Liu W, Li C, Tao W, Li L, Hu D. Genetic analysis of Brugada syndrome and congenital long-QT syndrome type 3 in the Chinese. J Cardiovasc Dis Res. 2010;1:69–74.CrossRefPubMedPubMedCentral
88.
89.
90.
Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35:569–82.CrossRefPubMed
91.
Aleksova A, Sabbadini G, Merlo M, Pinamonti B, Barbati G, Zecchin M, et al. Natural history of dilated cardiomyopathy: from asymptomatic left ventricular dysfunction to heart failure—a subgroup analysis from the Trieste Cardiomyopathy Registry. J Cardiovasc Med. 2009;10:699–705.CrossRef
92.
Merlo M, Caiffa T, Gobbo M, Adamo L, Sinagra G. Reverse remodeling in dilated cardiomyopathy: insights and future perspectives. IJC Hear Vasc. 2018;18:52–7.CrossRef
93.
Merlo M, Pivetta A, Pinamonti B, Stolfo D, Zecchin M, Barbati G, et al. Long-term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years. Eur J Heart Fail. 2014;16:317–24.CrossRefPubMed
94.
Bowles NE, Bowles KR, Towbin JA. The "final common pathway" hypothesis and inherited cardiovascular disease. Herz. 2000;25:168–75.CrossRefPubMed
95.
Towbin JA, Lorts A, Cincinnati O. Arrhythmias and dilated cardiomyopathy common pathogenetic pathways?*. J Am Coll Cardiol. 2011;57:2169–71.CrossRefPubMed
Metadaten
Titel
Genetics of Dilated Cardiomyopathy: Clinical Implications
verfasst von
A. Paldino
G. De Angelis
M. Merlo
M. Gigli
M. Dal Ferro
G. M. Severini
L. Mestroni
G. Sinagra
Publikationsdatum
01.10.2018
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 10/2018
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-018-1030-7

Weitere Artikel der Ausgabe 10/2018

Current Cardiology Reports 10/2018 Zur Ausgabe

Congenital Heart Disease (RA Krasuski, Section Editor)

Heart Transplantation and Mechanical Circulatory Support in Adults with Congenital Heart Disease

Interventional Cardiology (SR Bailey, Section Editor)

Update on Devices for Diastolic Dysfunction: Options for a No Option Condition?

Interventional Cardiology (SR Bailey, Section Editor)

Drug-Coated Balloons: Hope or Hot Air: Update on the Role of Coronary DCB

Myocardial Disease (A Abbate, Section Editor)

Treatment of Diabetes in Patients with Heart Failure

Echocardiography (JM Gardin and AH Waller, Section Editors)

Assessment of Left Atrial Function by Echocardiography: Novel Insights

Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)

Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise